Adenosquamous carcinoma of the lung
Revision as of 17:00, 22 December 2017 by Michael (talk | contribs) (→Biopsy - possible adenosquamous carcinoma)
Adenosquamous carcinoma of the lung, also lung adenosquamous carcinoma, is a rare epithelial derived malignancy of the lung with features of both adenocarcinoma and squamous cell carcinoma.
Adenosquamous carcinoma of the lung | |
---|---|
Diagnosis in short | |
Adenosquamous carcinoma of lung. H&E stain. | |
LM DDx | squamous cell carcinoma of the lung, adenocarcinoma of the lung |
Site | lung - see lung tumours |
| |
Prevalence | rare |
Clin. DDx | other lung tumours |
It is grouped with the non-small cell lung cancers.
General
- Rare.
- Respond to tyrosine kinase inhibitors.[1][2]
Microscopic
Features:[3]
- Adenocarcinoma component (>=10% of tumour ‡).
- Squamous cell carcinoma component (>=10% of tumour ‡).
Note:
- ‡ Criteria used by individual pathologists may vary and/or may not be uniformly applied.[3]
DDx:
- Squamous cell carcinoma of the lung.
- Adenocarcinoma of the lung.
- Metastatic adenosquamous carcinoma - requires history.
Images
www
Sign out
Biopsy - possible adenosquamous carcinoma
Left Upper Lobe of Lung, Core Biopsy: - NONSMALL CELL CARCINOMA, FAVOUR ADENOCARCINOMA, CANNOT EXCLUDE ADENOSQUAMOUS CARCINOMA. Comment: The tumour stains as follow: POSITIVE: TTF-1, CK5/6 (focal), p63, napsin A. NEGATIVE: (none). The positive staining (TTF-1 and napsin A versus CK5/6 and p63) appears to be in different tumour cells. The case was reviewed internally and there is agreement on the above interpretation.
Note:
- Cases should not be signed as adenosquamous carcinoma on biopsy, due to the percentage requirements (>=10% for both components) - see microscopic section.
See also
References
- ↑ Song, Z.; Lin, B.; Shao, L.; Zhang, Y. (Sep 2013). "Therapeutic efficacy of gefitinib and erlotinib in patients with advanced lung adenosquamous carcinoma.". J Chin Med Assoc 76 (9): 481-5. doi:10.1016/j.jcma.2013.05.007. PMID 23769878.
- ↑ Iwanaga, K.; Sueoka-Aragane, N.; Nakamura, T.; Mori, D.; Kimura, S. (2012). "The long-term survival of a patient with adenosquamous lung carcinoma harboring EGFR-activating mutations who was treated with gefitinib.". Intern Med 51 (19): 2771-4. PMID 23037472.
- ↑ 3.0 3.1 Rao, N. (Jul 2014). "Adenosquamous carcinoma.". Semin Diagn Pathol 31 (4): 271-7. doi:10.1053/j.semdp.2014.06.004. PMID 25002356.